Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 2011-2016

  Sun, Z ^a   Chen, J ^a,b,c   Aakre, J ^a   Marks, R S ^a   Garces, Y Y ^a   Jiang, R ^a   Idowu, O ^a,d   Cunningham, J M ^a   Liu, Y ^a,c   Pankratz, V S ^a   Yang, P ^a  

^a Mayo Clinic College of Medicine   (United States)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

DNA repair; Glutathione; Polymorphism; Small cell lung cancer; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; GLUTATHIONE; GLUTATHIONE SYNTHASE; GLUTATHIONE TRANSFERASE A3; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN ABCC1; PROTEIN ABCC2; PROTEIN ABCC3; PROTEIN ABCC4; PROTEIN RRM1; RAD52 PROTEIN; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; GLUTATHIONE METABOLISM; HAPLOTYPE; HUMAN; LUNG SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

EID: 77957105987     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq212     Document Type: Article

References (30)

1. Glisson BS, Hong WK. Survival after treatment of small-cell lung cancer: an endless uphill battle. J Natl Cancer Inst 1997; 89: 1745-1747.
2. Chen J, Jiang R, Garces YI et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer 2009; 67: 221-226.
3. Yang P, Ebbert JO, Sun Z, Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006; 24: 1761-1769.
4. Sreeja L, Syamala V, Hariharan S et al. Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients. J Exp Ther Oncol 2008; 7: 73-85.
5. Lu C, Spitz MR, Zhao H et al. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 2006; 106: 441-447.
6. Gonlugur U, Pinarbasi H, Gonlugur TE, Silig Y. The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome. Cancer Invest 2006; 24: 497-501.
7. Booton R, Ward T, Heighway J et al. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol 2006; 1: 679-683.
8. Sweeney C, Nazar-Stewart V, Stapleton PL et al. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003; 12: 527-533.
9. Yang P, Yokomizo A, Tazelaar HD et al. Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer 2002; 35: 221-229.
10. Soini Y, Napankangas U, Jarvinen K et al. Expression of gamma-glutamyl cysteine synthetase in nonsmall cell lung carcinoma. Cancer 2001; 92: 2911-2919.
11. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004; 14: 959-970.
12. Rosell R, Crino L, Danenberg K et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol 2003; 30: 19-25.
13. Wu X, Zhao H, Suk R, Christiani DC. Genetic susceptibility to tobacco-related cancer. Oncogene 2004; 23: 6500-6523.
14. Rosell R, Cuello M, Cecere F et al. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol 2006; 18: 135-143.
15. de las Penas R, Sanchez-Ronco M, Alberola V et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17: 668-675.
16. Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311-316.
17. Sun Z, Aubry MC, Deschamps C et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital-and 712 population-based cases. J Thorac Cardiovasc Surg 2006; 131: 1014-1020.
18. Yang P, Allen MS, Aubry MC et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997-2003. Chest 2005; 128: 452-462.
19. Storey JD. A direct approach to false discovery rates. J R Stat Soc Series B 2002; 64: 479-498.
20. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003; 100: 9440-9445.
21. Schaid DJ, Rowland CM, Tines DE et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70(2): 425-434.
22. Kiyotani K, Mushiroda T, Kubo M et al. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008; 99: 967-972.
23. Han JY, Lim HS, Yoo YK et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138-147.
24. Gurubhagavatula S, Liu G, Park S et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594-2601.
25. Giachino DF, Ghio P, Regazzoni S et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 2007; 13: 2876-2881.
26. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
27. Gazdar AF. DNA repair and survival in lung cancer-the two faces of Janus. N Engl J Med 2007; 356: 771-773.
28. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-4943.
29. Yoon SM, Hong CY, Park HJ et al. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 885-891.
30. Yu D, Zhang X, Liu J et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res 2008; 14: 2878-2886.